Patricia A. Deverka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Patricia A. Deverka has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
HL McLeod
University of North Carolina at Chapel Hill UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics North Carolina USA
1 shared publicationHoward L. McLeod
UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, Division of Hematology and Oncology, Department of Health Policy and Management, and the Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599
1 shared publicationJohn Vernon
UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, Division of Hematology and Oncology, Department of Health Policy and Management, and the Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599
1 shared publication
Latest Publications
- 1 February 2010
- Published by Annual Reviews in Annual Review of Pharmacology and Toxicology
- Vol. 50 (1) , 423-437
Economic Opportunities and Challenges for Pharmacogenomics
Economic evaluation provides health care decision makers with a powerful tool for resource allocation decisions because it offers a framework for comparing the costs and benefits of competing interventions or options. This paper reviews how economic analyses have been applied to the field of pharmacogenomics, both by the pharmaceutical industry to inform investment decisions and by payers to make coverage decisions. There is much anticipation that pharmacogenomic testing is likely to be cost-effective because it uses genomic information to improve drug effectiveness and reduce toxicity both in the drug development process and at the bedside. However, the demonstration of economic benefits first requires that pharmacogenomic testing show evidence of clinical effectiveness. This will only be achieved by greater participation of pharmacogenomics experts in comparative effectiveness research and additional emphasis on including costs in the determination of the relative value of pharmacogenomic testing to the health care system.
- 1 February 2010
- Published by Annual Reviews in Annual Review of Pharmacology and Toxicology
- Vol. 50 (1) , 423-437
Economic Opportunities and Challenges for Pharmacogenomics
Economic evaluation provides health care decision makers with a powerful tool for resource allocation decisions because it offers a framework for comparing the costs and benefits of competing interventions or options. This paper reviews how economic analyses have been applied to the field of pharmacogenomics, both by the pharmaceutical industry to inform investment decisions and by payers to make coverage decisions. There is much anticipation that pharmacogenomic testing is likely to be cost-effective because it uses genomic information to improve drug effectiveness and reduce toxicity both in the drug development process and at the bedside. However, the demonstration of economic benefits first requires that pharmacogenomic testing show evidence of clinical effectiveness. This will only be achieved by greater participation of pharmacogenomics experts in comparative effectiveness research and additional emphasis on including costs in the determination of the relative value of pharmacogenomic testing to the health care system.
- Open Access
- 1 February 2009
- Published by S. Karger AG in Public Health Genomics
- Vol. 12 (3) , 149-157
Pharmacogenomics, Evidence, and the Role of Payers
Initial enthusiasm for the potential of pharmacogenomics (PGx) to transform medical practice has been tempered by the reality that the process of biomarker discovery, validation, and clinical qualification has been disappointingly slow, with a limited number of PGx tests entering the marketplace since the initial publication of the human genome sequence. Reasons for the delays include the complexity of the underlying science as well as clinical, economic, and organizational barriers to the effective delivery of personalized health care. Nevertheless, payers are interested in using PGx services to ensure that drug use is safer and more effective, particularly in the settings of medications that are widely used, have significant risks of serious adverse events, have poor or highly variable drug response, or are very expensive. However, public and private payers have specific evidence requirements for new health care technologies that must be met prior to obtaining favorable coverage and reimbursement status. These evaluation criteria are frequently more rigorous than the current level of evidence required for regulatory approval of new PGx tests or PGx-related drug labeling. To support payer decision-making, researchers will need to measure the impact of PGx testing on clinical and economic outcomes and demonstrate the net benefit of PGx testing as compared to usual care. By linking payer information needs with the current PGx research agenda, there is the opportunity to develop the data required for informed decision-making. This strategy will increase the likelihood that PGx services will be both reimbursed and used appropriately in clinical practice.
- 1 February 2009
- Published by S. Karger AG in Public Health Genomics
- Vol. 12 (3) , 149-157
Open AccessPharmacogenomics, Evidence, and the Role of Payers
Initial enthusiasm for the potential of pharmacogenomics (PGx) to transform medical practice has been tempered by the reality that the process of biomarker discovery, validation, and clinical qualification has been disappointingly slow, with a limited number of PGx tests entering the marketplace since the initial publication of the human genome sequence. Reasons for the delays include the complexity of the underlying science as well as clinical, economic, and organizational barriers to the effective delivery of personalized health care. Nevertheless, payers are interested in using PGx services to ensure that drug use is safer and more effective, particularly in the settings of medications that are widely used, have significant risks of serious adverse events, have poor or highly variable drug response, or are very expensive. However, public and private payers have specific evidence requirements for new health care technologies that must be met prior to obtaining favorable coverage and reimbursement status. These evaluation criteria are frequently more rigorous than the current level of evidence required for regulatory approval of new PGx tests or PGx-related drug labeling. To support payer decision-making, researchers will need to measure the impact of PGx testing on clinical and economic outcomes and demonstrate the net benefit of PGx testing as compared to usual care. By linking payer information needs with the current PGx research agenda, there is the opportunity to develop the data required for informed decision-making. This strategy will increase the likelihood that PGx services will be both reimbursed and used appropriately in clinical practice.
- 1 August 2008
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 84 (2) , 191-193
Harnessing Economic Drivers for Successful Clinical Implementation of Pharmacogenetic Testing
Before pharmacogenetic (PGx) testing has a major impact on clinical practice, two levels of evidence must be generated. First, studies demonstrating the links between genetic variation and response to medications in defined populations are needed, along with development of valid tests to measure these specific variants. Second, studies should be conducted to evaluate whether PGx testing improves health outcomes for patients and whether the decision to test is cost-effective relative to usual care. This latter set of questions is typically of greatest relevance to clinicians and payers, the ultimate gatekeepers for the clinical integration of pharmacogenetics. To date, nearly all of the research efforts and funding for PGx have been focused on the first set of issues-getting the science right. However, now is the time to increase our research efforts on the second set of issues-to improve the PGx evidence base for both clinical and economic decision making.
- 1 August 2008
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 84 (2) , 191-193
Harnessing Economic Drivers for Successful Clinical Implementation of Pharmacogenetic Testing
Before pharmacogenetic (PGx) testing has a major impact on clinical practice, two levels of evidence must be generated. First, studies demonstrating the links between genetic variation and response to medications in defined populations are needed, along with development of valid tests to measure these specific variants. Second, studies should be conducted to evaluate whether PGx testing improves health outcomes for patients and whether the decision to test is cost-effective relative to usual care. This latter set of questions is typically of greatest relevance to clinicians and payers, the ultimate gatekeepers for the clinical integration of pharmacogenetics. To date, nearly all of the research efforts and funding for PGx have been focused on the first set of issues-getting the science right. However, now is the time to increase our research efforts on the second set of issues-to improve the PGx evidence base for both clinical and economic decision making.